tiprankstipranks

Autolus Therapeutics reports Q1 EPS (24c), consensus (5c)

Reports Q1 revenue $10.091M vs $1.292M last year. “We continue to engage with the FDA in the regulatory review process for obecabtagene autoleucel in adult ALL as we head towards the PDUFA target action date of November 16, 2024, and are driving commercial readiness activities across the Company,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “We’re also delighted that our abstracts from the pivotal FELIX Phase 2 trial have been accepted for oral presentations at ASCO and EHA this year and we look forward to sharing further long-term data and additional subset analyses.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue